Entelexo Biotherapeutics

Entelexo Biotherapeutics, founded in 2020 and located in Irvine, CA, operates within the healthcare industry, focusing on the therapeutics sub-sector. The company has developed a unique platform that utilizes engineered exosomes to facilitate cell-to-cell communication, targeting multiple specific diseased cells simultaneously, which is crucial for treating complex autoimmune diseases like Rheumatoid Arthritis, Crohn’s Disease, and Psoriasis. These diseases affect millions and are currently incurable due to their complexity involving various cell types and pathways.

Entelexo has rapidly prototyped therapeutics for various autoimmune conditions, leveraging a proprietary engineering platform to develop exosome-based therapeutics. The company has built an initial pipeline of products, selected lead drug candidates, and de-risked these candidates using human cell immunoassays. Entelexo has completed proof of concept testing, filed multiple patents, and began IND-enabling animal studies with preparations to file for Pre-IND with the FDA in 2023. Additionally, the company has been recognized at the JP Morgan biotech showcase and won the Pitch.Launch.Grow. Biotech Competition, underscoring its innovative approach in the biotechnology field.